<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250421065424N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-09-08</date_registration>
      <primary_sponsor>Bandare-abbas University of Medical Sciences</primary_sponsor>
      <public_title>Effect of B complex in analgesia of orthopedic patients</public_title>
      <acronym></acronym>
      <scientific_title>Preventive analgesic effect of vitamin B complex in combination with fentanyl in patients undergoing fixation surgery for lower leg fractures</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83447</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this prospective study, participants will be randomly assigned to either the intervention or control group using block randomization. The unit of randomization is individual, meaning each participant will be independently randomized. To generate the random allocation sequence, R statistical software will be used to create blocks of varying sizes (e.g., 4 and 6), ensuring balanced group sizes throughout enrollment.
If key confounding variables such as age or gender are identified, stratified randomization will be applied within each stratum to achieve balanced distribution across groups.
The randomization process will be implemented using sealed, opaque envelopes, prepared by an independent third party not involved in participant recruitment. Each envelope will contain the group assignment code and will be opened only after the participant’s eligibility is confirmed and baseline data are recorded. This approach ensures proper allocation concealment and minimizes selection bias.
No quasi-random methods (e.g., assignment based on birth date or record number) will be used in this study. All randomization steps are designed to follow rigorous standards for true random allocation, Blinding description: This study employed single-blinding where patients were unaware of their group assignment (vitamin B complex + fentanyl vs fentanyl + placebo). Study medications were administered in identical, unmarked syringes, and postoperative evaluations were performed by independent nurses to maintain blinding.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Tibial Fracture. Condition 2: Postoperative Pain. Condition 3: Pain Prevention.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in this group receive an intramuscular injection of vitamin B complex (BECOVIT 2ml ampoule) prior to the start of surgery.The ampoule contains: 4 mg vitamin B1, 4 mg vitamin B2, 4 mg vitamin B6, 40 mg nicotinamide, and 6 mg dexpanthenol.Manufactured by Exir Pharmaceutical Company, Iran.The medication is administered once before the orthopedic surgery for lower limb fracture fixation. Intervention 2: Control group:Patients in this group will receive normal saline with the same volume as the intervention group before the surgery, instead of vitamin B complex. All other procedures including premedication, induction of anesthesia, intraoperative medications, vital sign monitoring, and postoperative care will be identical to the intervention group. Pain intensity, blood pressure, heart rate, and need for rescue analgesics will be assessed and recorded at specified time intervals after surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
De-identified individual participant data (IPD), study protocol, informed consent form, statistical analysis plan, analysis codes, clinical study report, and data dictionary will be shared after study completion. The shared data will include key outcome variables and demographic information, with all personal identifiers removed.

When:
Access to the data and documents will begin 6 months after the publication of the main study results and will remain available for 5 years.

To whom:
Academic researchers, members of recognized research institutions, and professionals in the pharmaceutical and healthcare industries with a defined scientific purpose may request access.

Conditions:
Data may only be used for research and scientific analysis purposes. Applicants must submit a research proposal and sign a data use agreement ensuring ethical compliance and confidentiality. Commercial use of the data is not permitted.

Where to obtain:
Requests should be directed to the corresponding author, Dr. Jerry Neshin.
Address: Islamic Republic Boulevard, Shahid Mohammadi Hospital, 5-Story Building, First Floor, Anesthesiology Research Center
Phone: +98 76 3334 3862
Email: anrc.hums@gmail.com

How to obtain:
Upon receiving a request, the ethics committee and research team will review it within 2 weeks. If approved, a data use agreement will be sent. Once signed, the data will be shared within another 2 weeks. The entire process takes approximately 4 weeks.

Comments:
For further information or to request additional documents, please contact the corresponding author via email.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Jamalizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 1, Hospital St., Imam Hossein Blvd., Shahid Mohammadi Hospital, Bandar Abbas</address>
        <city>Bandar Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7915843661</zip>
        <telephone>+98 76 3367 0000</telephone>
        <email>fjamali351@gmail.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hashem Jarineshin</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 1, Hospital St., Imam Hossein Blvd., Payambar Azam Educational and Medical Complex, Bandar Abbas</address>
        <city>Bandar Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7915843661</zip>
        <telephone>+98 76 3334 5009</telephone>
        <email>hjarineshin@yahoo.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients aged 18 to 65 with ASA I-II, who were candidates for elective orthopedic surgery for fracture fixation of the tibia, were included.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>emergency cases
those allergic to vitamin B complex
those with a history of analgesic use
drug addicts
patients with cardiac/hepatic/renal failure
hemodynamically unstable patients
those with multiple fractures</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S82.201A</hc_code>
      <hc_code>G89.18</hc_code>
      <hc_code>R52</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified fracture of shaft of right tibia, initial encounter for closed fracture</hc_keyword>
      <hc_keyword>Other acute postprocedural pain</hc_keyword>
      <hc_keyword>Pain, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in this group receive an intramuscular injection of vitamin B complex (BECOVIT 2ml ampoule) prior to the start of surgery.The ampoule contains: 4 mg vitamin B1, 4 mg vitamin B2, 4 mg vitamin B6, 40 mg nicotinamide, and 6 mg dexpanthenol.Manufactured by Exir Pharmaceutical Company, Iran.The medication is administered once before the orthopedic surgery for lower limb fracture fixation</i_keyword>
      <i_keyword>Control group:Patients in this group will receive normal saline with the same volume as the intervention group before the surgery, instead of vitamin B complex. All other procedures including premedication, induction of anesthesia, intraoperative medications, vital sign monitoring, and postoperative care will be identical to the intervention group. Pain intensity, blood pressure, heart rate, and need for rescue analgesics will be assessed and recorded at specified time intervals after surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity in patients undergoing lower limb fracture fixation surgery at 1, 6, 12, and 24 hours postoperatively, measured using the Visual Analogue Scale. Timepoint: At 1, 6, 12, and 24 hours after the end of surgery. Method of measurement: Visual Analogue Scale (VAS) ranging from 0 to 10.</prim_outcome>
      <prim_outcome>Requirement for specific analgesic medication (pethidine) in patients undergoing lower limb fracture fixation surgery at 1, 6, 12, and 24 hours postoperatively. Timepoint: At 1, 6, 12, and 24 hours after the end of surgery. Method of measurement: Documentation of intravenous administration of 25 mg pethidine when pain intensity exceeds 3 on the Visual Analogue Scale, recorded by an anesthesiology staff member.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Systolic blood pressure in patients undergoing lower limb fracture fixation surgery during recovery (at 0, 15, 30, and 60 minutes postoperatively). Timepoint: At 0, 15, 30, and 60 minutes after the end of surgery in the recovery room. Method of measurement: Measurement of systolic blood pressure using non-invasive blood pressure monitor (NIBP) via operating room monitoring system.</sec_outcome>
      <sec_outcome>Heart rate in patients undergoing lower limb fracture fixation surgery during recovery (at 0, 15, 30, and 60 minutes postoperatively). Timepoint: At 0, 15, 30, and 60 minutes after the end of surgery in the recovery room. Method of measurement: Measurement of heart rate using electrocardiogram (ECG) monitoring in the operating room.</sec_outcome>
      <sec_outcome>Diastolic blood pressure in patients undergoing lower limb fracture fixation surgery during recovery (at 0, 15, 30, and 60 minutes postoperatively). Timepoint: At 0, 15, 30, and 60 minutes after the end of surgery in the recovery room. Method of measurement: Measurement of diastolic blood pressure using non-invasive blood pressure monitor (NIBP) via operating room monitoring system.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bandare-abbas University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-02-12</approval_date>
        <contact_name>Ethics Committee of Hormozgan University of Medical Sciences</contact_name>
        <contact_address>No. 1, Kamarbandi Street, Islamic Republic Boulevard, opposite County Health Center, Shahid Mohammadi Hospital, Bandar Abbas, Hormozgan Province Bandar Abbas Hormozgan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
